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Hemodialysis encephalopathy with osteomalacic fractures and
muscle weakness. The hemodialysis unit at Columbia, South Car-
olina, opened in April, 1974. By June of 1977, 7 patients had died
from dialysis encephalopathy, and 16 of the 51 surviving patients
showed speech disorders, fits, and myoclonic jerks. Pathologic
fractures were seen in 22 patients. Bone histomorphometry
showed severe osteomalacia with minimal, if any, osteitis fi-
brosa, and serum alkaline phosphatase activity was normal. The
mean serum aluminum concentration in 33 random patients was
elevated at 83.5 isg/liter (control group, 13.9 gIliter, P <0.001).
The mean bone aluminum concentration in 4 patients who died
from this syndrome was 307 ppm of bone ash (normal, < 10
ppm). Dialysis fluid aluminum was high at 140 pg/liter. Purifica-
tion of the dialysis fluid with a water softener, reverse osmosis
and a deionizer and abandoning extra-strength Basaljel result-
ed in a notable clinical and EEG improvement. None of 81 new
patients who started hemodialysis between July of 1977 and July
of 1979 after the change in treatment have developed any such
symptoms. A syndrome of hemodialysis encephalopathy accom-
panied by pathologic osteomalacic fractures is described. Recov-
ery is possible. The syndrome was eradicated after purification
of the dialysis fluid.
Encéphalopathie de l'hémodialyse avec fractures ostéomala.
ciques et faiblesse musculaire. Le centre d'hémodialyse a Colum-
bia, South Carolina, USA, a ouvert en Avril 1974. De cette date
a Juin 1977, 7 malades étaient morts d'encéphalopathie de la
dialyse et 16 des 51 malades survivants avaient des troubles
du langage, des convulsions et des secousses myocloniques.
Des fractures pathologiques ont été observées chez 22 malades.
L'histomorphométrie osseuse a montré une ostéomalacie sévère
avec peu ou pas d'ostéite fibreuse. Les phosphatases alcalines
sériques étaient normales. La concentration moyenne d'alumini-
urn dans le serum chez 33 malades choisis au hasard était élevée
a 83,5 pg/liter (groupe contrôle: 13,9 gIliter, P < 0,001). La
concentration osseuse moyenne chez 4 malades décédés de ce
syndrome était de 307 ppm de résidu sur de l'os (normal < 10
ppm). L'aluminium du liquide de dialyse était élvé, a 140 gIliter.
La purification du liquide de dialyse au moyen d'un adoucisseur,
de l'osmose inverse et d'un désionisant et l'abandon du Basaijel®
ont eu pour consequence une amelioration importante, clinique
et électromyographique. Aucun des 81 nouveaux malades dont
l'hémodialyse a commence entre Juillet 1977 et Juillet 1979, après
la modification de Ia strategic, n'a développé de tels symptômes.
Un syndrome d'encéphalopathie de l'hémodialyse associé a des
fractures pathologiques ostéomalaciques est décrit. La récupéra-
tion est possible. Ce syndrome a disparu aprés la purification du
liquide de dialyse.
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Dialysis encephalopathy characterized by epi-
sodes of abnormal speech, myoclonic jerks, and
convulsions was first described by Aifrey et al in
1972 [1]. Since then it has been confirmed by dial-
ysis centers throughout the world [2—7]. Early re-
ports described the encephalopathic aspects of the
disease, but recent studies, mainly in Europe, in-
dicate that these patients may also show an in-
creased incidence of osteomalacic fractures with
muscle weakness [3-5, 8-10] and also a dispropor-
tionately severe anemia [10]. Platts, Moorhead, and
Greech in Sheffield, England, first suggested a pos-
sible link between dialysis encephalopathy and
pathologic fractures and speculated that a toxic con-
taminant in the dialysis fluid could be responsible
for both of these complications [11]. Flendrig,
Kruis, and Das [4] in Eindhoven, Holland, also
commented on the unusually high incidence of frac-
tures in their hemodialysis unit affected by dialysis
dementia. When the source of aluminum in the dial-
ysis fluid was removed, the development of patho-
logic fractures stopped, and dialysis encephalop-
athy ceased to be a problem. The reason for these
fractures remained obscure until work at the Uni-
versity of Newcastle Upon Tyne, another hemo-
dialysis center affected by the above two complica-
tions, showed them to be the result of a severe form
of osteomalacic bone disease [8, 12, 13] resistant to
treatment with dihydrotachysterol [14], 1a-hydroxy-
cholecalciferol [15] or la-hydroxycholecalciferol
with phosphate supplements [16].
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In the USA, the association between dialysis en-
cephalopathy and pathologic fractures is not widely
recognized. The purpose of this report is to describe
the clinical features of this syndrome as it occurred
in Columbia, South Carolina, together with the
therapeutic steps that led to its elimination. Serum
aluminum concentrations were measured serially
starting at the peak of the illness, and they were
compared to those found in patients on long-term
haemodialysis at the Mayo Clinic, a center where
dialysis encephalopathy and osteomalacic fractures
are exceedingly rare. The study was approved by
the Mayo Clinic Human studies Committee [HSC
164—77].
Methods
The Columbia hemodialysis center opened in
April of 1974, and by July of 1977, 94 patients had
started on long-term hemodialysis with a dialysate
solution containing 3.5 mEq/liter of calcium and
prepared from city tap water obtained from the
Broad River. To purify this city water, the Colum-
bia Water Department regularly adds aluminum sul-
phate, the daily dose over the last 5 years ranging
between 0.7 and 6.0 g of aluminum sulphate per gal-
lon of water. Patients were also prescribed extra-
strength Basaijel, 60 to 100 mllday. By the end of
1976, several patients were noted to become ill on
hemodialysis, with frequent myoclonic jerks, con-
vulsions, and abnormal speech, and some of them
deteriorated rapidly to death. In July of 1977, all
surviving hemodialysis patients were reexamined,
with attention paid to the presence of proximal
muscle weakness and pathologic fractures. A radio-
logic skeletal survey and a standard electroenceph-
alogram were obtained in all 51 surviving patients.
Serum creatinine, blood urea nitrogen [BUN], cal-
cium, and phosphorus concentrations and alkaline
phosphatase activity both before and at the end of
hemodialysis were recorded on 2 consecutive
weeks. Quantitative bone histomorphometry as
previously described [17] was carried out on sam-
ples obtained at autopsy in 4 patients who died from
this syndrome, and on 2 other encephalopathic pa-
tients who consented to a transiliac bone biopsy.
Fasting serum aluminum concentration was mea-
sured in 33 random surviving hemodialysis patients
by a flameless atomic absorption spectrophotome-
ter capable of measuring serum aluminum at a con-
centration of 5 g!liter (reference range, 13.9
[SD] 6.2 jig/liter). Tissue aluminum concentration
was measured at the Atomic Weapons Research Es-
tablishment, Aldermaston, United Kingdom, by an
accurate neutron activation technique [18]. Speci-
mens of the dialysate fluid in July of 1977 were
found to contain an average of 140 gI1iter of alumi-
num.
After July, 1977. After the above baseline mea-
surements were made, all extra-strength Basaijel
was stopped (100 ml of extra-strength Basaljel con-
tains approximately 7 g of elemental aluminum,
whereas 100 ml of standard Basaijel contains ap-
proximately 2 g of elemental aluminum), and a new
water purification plant was installed. A prefilter
was used to remove particles over 10 and this was
followed by softener, activated carbon, and a re-
verse osmosis (Continental model 3030). In this
way, all total dissolved solids were reduced to
about 6 ppm, and a deionizer was then added to re-
move any remaining solids to less than 0.Olppm.
The treated water showed an electric resistance of
about 18 megaohms, and no aluminum could be de-
tected. This water purification plant became opera-
tional in October 1977, and at that time standard Ba-
saljel (500 mg) capsules, 2 to 6 per day, were pre-
scribed again in order to keep the patients'
predialysis serum phosphrus concentration be-
tween 4.0 and 6.0 mg/dl and the postdialysis serum
phosphorus not less than 2.5 mgldl. All patients
were reassessed in December 1977, April 1978, July
of 1978, and July of 1979, after which the present
report was prepared.
Results
Table 1 presents a detailed analysis of all 175 pa-
tients who started repetitive hemodialysis between
April 1974 and July 1979. Ninety-four patients
started hemodialysis between April 1974 and July
1977, and the remaining 81 patients started hemo-
dialysis after the change in management. By July
1977, 7 patients had died from causes directly attrib-
utable to dialysis dementia. At the same time, 16 of
the 51 surviving patients dialyzing at the unit
showed intermittent speech abnormalities with con-
vulsions and myoclonic jerks. Of these 16 patients,
5 were severely affected, being restricted to a
wheelchair or bedridden, and 4 of these died within
the next 5 months, making a total of 11 patients who
died from dialysis encephalopathy. During the 2
years after change in treatment, none of the 35 pre-
viously asympatomatic patients and none of the 81
new patients developed any symptoms of dialysis
encephalopathy. At the same time, there was gener-
al improvement in the patients' myopathic symp-
toms, and after 9 months of using purified dialysate
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fluid there was a significant rise in the patients' he-
matocrit (baseline Hct, 25.5; Hct after 9 months of
treatment, 29.5, P < 0.001).
Table 2 presents the clinical characteristics,
length on repetitive hemodialysis, EEG, radiologic,
Table 1. Outcome of all hemodialysis patients at Columbia,
South Carolina, up to July l979
By
July 1977
By
July 1978
April 1974 to July 1977 (94 patients)
Alive and dialyzing in center 51b 32
Transferred elsewhere 15 17
Transplanted 6 13
Home-trained 4 8
Died 18e 24d
Total 94 94
July 1977 to June 1978 (38 patients)e
July 1978 to July 1979 (43 patients)e
a Ninety-four patients joined the program up to July 1977, 38
between July 1977 and June 1978, and 43 between July 1978 and
July 1979. None of the 81 new patients after July 1977 developed
any symptoms of dialysis encephalopathy.
b Of the 51 patients, 16 had symptoms of dialysis encephalop-
athy.
Seven patients died from dialysis encephalopathy, 11 from
other causes.
d Eleven patients died from dialysis encephalopathy, 13 from
other causes.
None of these new patients developed dialysis encephalop-
athy.
and histologic findings in the 11 patients who died
from dialysis encephalopathy. There were 7 male
and 4 female patients with a mean age of 58.8 years
(range, 47 to 70). Their mean survival on hemo-
dialysis was 20.6 months [range, 3 to 29]. In 3 of the
patients, a subtotal parathyroidectomy had been
carried out, but this did not appear to have a benefi-
cial effect on the progression of their disease, and
the patients died 4, 4 and 8 months later. EEG ab-
normalities were found in all 9 patients in whom
tracings were recorded. The most common and pos-
sibly earliest EEG abnormality was slowing of the
basic brain rhythm into the theta and delta frequen-
cy, and at later stages protracted irregular delta ac-
tivity appeared. Superimposed on this diffuse slow-
ing, there was generalized high voltage paroxysmal
rhythmic delta activity. In the terminal stages of
some cases, continuous periodic complexes were
seen (Fig. 1). Skeletal radiographs in these 11 pa-
tients showed extensive pathologic fractures af-
fecting commonly the femoral neck (Fig. 2), pubic
rami, metatarsals, and ribs. None of these patients
showed subperiosteal erosions on hand radio-
graphs. Quantitative bone histology showed severe
osteomalacia and minimal, if any, osteitis fibrosa
(Fig. 3, a and b and Fig. 4 a-d). Thin bone trabe-
culae (Fig. 5) were covered by excessive osteoid,
almost devoid of any osteoblastic activity, and their
Table 2. Clinical characteristics and EEG, radiologic, and histologic findings in the 11 patients who died from dialysis encephalopathy
Onset of Period
dialysis at on
Age Columbia, Date of dialysis Osteitis Osteo-Case yr Sex Race Diagnosis S.C. death months EEG SPEe Fractures/loozer zones fibrosa malacia
1 63 M W Chronic GN May 1974 Sept 1976 28 Not done None Ribs, left clavicle,
left shoulder
2 70 M W Chronic GN May 1974 June 1977 27 Pos. None Multiple rib fractures
3 47 M N Chronic GN June 1974 Jan 1976 19 Not done None Right femoral neck
4 47 F N Chronic GN Apr 1975 June 1977 26 Pos. None Right femoral neck/ None
leftclavicle
Severe
5 67 F N Chronic GN Apr 1975 Sept 1977 29 Pos. None Right scapula/marked
scoliosis6 62 F W
7 56 F N
Interst.
nephritis
Interst.
nephritis
July 1975
Oct 1975
July 1977
Oct 1977
24
24
Pos.
Pos.
None
None
Pubic rami, multiple ribs,
collapsed thoracic cage
Pubic rami, left humeral
head, 2nd metatarsal,
right and left metacarpals
F' b 49 M W Chronic GN Dec 1975 Aug 1977 20 Pos. None Multiple ribs None Moderate
9C 55 M N Chronic GN Jan 1976 Dec 1977 23 Pos. None Rt. femoral neck Minimal Severe
10 66 M N Chronic GN Jan 1977 May 1977 4 Pos. None None seen on available Minimal
chestX-ray
Moderate
11d 65 M N Nephro-
sclerosis
Apr 1977 July 1977 3 Pos. None None seen on available Minimal
chest X-ray
Severe
a Patients received a subtotal parathyroidectomy without any noticeable improvement.
Acute hyperkalemia and death
Seizure—fractured right femoral neck—postoperative death
Pericarditis. Low cardiac output failure—operative death
SPE is subperiosteal erosions.
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Coma seizure status 1 sec
Patient did not recover and died soon after
Fig. 1. EEG of patient 10 (Table 2) taken in May 1977 3 days prior to his death. It illustrates the very irregular almost continuous
paroxysmal delta activity with large voltage slow waves seen occasionally in such advanced patients.
Fig. 2. X-ray of pelvis showing pathologic fractures of the right and left femoral necks.
mineralization fronts were abnormally low (Table
3).
Table 4 describes the progressive clinical findings
in the 16 surviving encephalopathic patients after
July 1977. Four of these patients, patients 13 to 16,
died before or shortly after the installation of the
water purification plant, but the remaining 12 pa-
tients made a steady clinical and EEG improve-
ment. Two patients have since died from causes un-
related to dialysis encephalopathy, but the remain-
ing 10 patients remain in good health 2 years later.
Comparison of the mean pre- and post-dialysis bio-
chemical findings between encephalopathic and
nonencephalopathic patients was made in June 1977
before any change in treatment (Table 5). All pa-
tients appeared adequately dialyzed by standard
criteria relating to serum creatinine and blood urea
nitrogen, and no significant biochemical differences
could be demonstrated between the two groups.
Table 6 summarizes the results of all radiologic
skeletal surveys and emphasizes the striking ab-
sence of subperiosteal erosions together with the
unusually high prevalence of pathologic fractures in
this hemodialysis population. Thirty-three percent
of all patients had pathologic fractures, the in-
cidence rising to 70% in the encephalopathic group.
Clinical myopathy was detected in 60% of all pa-
tients and in 100% of all encephalopathic patients.
Clinical myopathy was accompanied by brisk deep-
tendon reflexes.
Figure 6 compares the results of serial measure-
ments of serum aluminum in patients dialyzing at
Columbia, South Carolina, and the Mayo Clinic.
The initial mean serum aluminum at Columbia was
83.5 27 sgIliter, significantly higher than the
mean for normal controls and also that of patients
dialyzing at the Mayo Clinic where a water soft-
ener, reverse osmosis, and a deionizer have been
used for a decade. By December 1977, 2 months af-
ter the installation of the water purification plant
and after a reduction in the consumption of extra-
strength Basaljel, serum aluminum decreased sig-
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Fig. 3. Histologic sections of undecalcified bone of patient 11 sections illustrate the significant osteomalacia present with ex-
(Table 2) and patient 12 (Table 4) (magnification, X80). Goidner cess osteoid covering almost every trabecular surface.
stain showing osteoid dark and mineralized bone light. These
Fig. 4 A-D. Photomicrographs qf thin 5-p.-thick bone sections stained to show the severe osteomalacia. A and B Stained with Goldner's
stain. Osteoid shows as red and the mineralized bone shows as green (magnification, A x20; B x50). C Stained with von Kossa and
toluidene blue (osteoid light blue; mineralized shows as black). This figure shows excessive surface osteoid and previous resorption areas
now covered by inactive osteoid (magnification, x50). D Same stain viewed with a polarizer. It shows the greatly increased number of
birifringent lamellae. Excess surface osteoid is lamellar (magnification x50).
nificantly, and the levels remained low in April pared to normal controls (mean bone aluminum,
1978. Iliac crest bone aluminum concentrations in <10 ppm of bone ash). These values were similar to
patients 4, 8, 10, 11 (Table 2) were 680, 123, 190, thosefoundinsimilarlyaffectedpatientsseenatthe
and 237 ppm of bone ash, significantly higher com- University of Newcastle Upon Tyne [18]. The fifth
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Fig. 5. Microradiograph of transiliac bone biopsy of patient 4 (Table 2) (right panel) compared with age and sex matched control (left
panel). It illustrates the marked osteoporosis present in these patients. (Magnification, x4.) Courtesy of Dr. Jenifer Jowsey.
patient (patient 10, Table 2), had an elevated brain,
frontal lobe, gray matter aluminum concentration of
5.4 mg/kg (normal, < 1.5 mg/kg).
Discussion
Clinical features: EEG findings. The present
study confirms the characteristics of dialysis en-
cephalopathy as previously described [1-4, 6-9, 19-
23] and for the first time in the USA documents its
association with an unusual variety of hemodialysis
osteomalacia responsible for pathologic fractures,
skeletal pain, and muscle weakness that is unre-
sponsive to treatment with vitamin D.
Another original and rewarding finding in this
study has been the long-term clinical and electroen-
cephalographic improvement observed in 10 of the
16 surviving encephalopathic patients (Table 4).
Earlier reports [1, 3, 7, 10, 20—23] had indicated an
invariable progression to death even after the resto-
ration of normal kidney function with a successful
kidney transplant [3, 5, 9, 24, 25]. Contrary to this
and in agreement with a previous report [26], the
present experience confirms that recovery may be
Table 3. Results of quantitative bone histomorphometry in six patients dialyzed at Columbia, South Carolinaa
Patient 4
(Table 2)
Patient 8
(Table 2)
Patient 9
(Table 2)
Patient 10
(Table 2)
Patient 12
(Table 4)
Patient 11
(Table 2) ControV
Percent measured area occupied by
Total bone 7.4 11.9 16.6 13.1 26.3 22.9 22.7 3.1
Mineralized bone 5.8 10.7 14.4 10.4 20.0 15.1 22.6 3.0
Osteoid 1.6 1.2 2.2 2.7 6.3 7.8 0.13 0.1
Percent mineralization of
cancellous bone 77.9 90.1 87.0 79.6 76.0 65.8 99.5 0.4
Maximum no. of osteoid lamellae 9 8 10 5 8 10 4
Percentage of cancellous bone
surfacecoveredbyosteoid 65.8 33.4 43.9 84.1 66.4 82.1 13.1 7.9%
Percentage of surface osteoid
bearingacalcificationfront 38.2 35.5 35.7 44.9 37.8 29.3 >60%
Osteomalacia + + + + + +
Osteoclasts,no./mm2 0.30 0.02 0.46 0.03 0.88 0.40 0.08 0.06
Osteitisfibrosagrade 0 0 1.5 0 1 1.5 0
a These show extensive osteomalacia with excess osteoid, increased number of osteoid lamellae, and a reduced percentage mineral-
ization front. Osteitis fibrosa is absent or minimal.
" Values are the means sn.
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Table 4. Clinical features and progression of 16 encephalopathic patients in June 1977a
June 1977 Dec. 1977 April 1978 July 1978
Sp Myo Ep Sp Myo Ep Sp Myo EpPatient no. Sp Myo Ep
I +++ ++ + ++ ++ + + + + —
2 + + + + + + + — Expired 3/78
3 ++ ++ ++ — — — — —
4 — ++ — — + — — — — — — —
5 — — ++ Transplanted Expired
6 ++ + ++ — + — — — — — — —
7 — ++ ++ — + — — — — —
8 ++ ++ — — + — — — — — + —
9 — ++ ++ — + — — — — — —
10 ++ ++ ++ + + + + + — + + —
11 ++ ++ ++ ++ ++ + + ++ — + +
12 ++ ++ ++ + + + + — —
13 +++ +++ +++ Expired 9/77
14 +++ +++ +++ Expired 10/77
15 + + + + + + + + + Expired 8/77
16 +++ +++ +++ Expired 12/77
a Abbreviations are: Sp, speech disorders; Myo, myoclonic jerks; Ep, epilepsy.
Table 5. Biochemical findings and comparison between encephalopathic and nonencephalopathic patients in June/July l977'
Encephalopathic patients Normal patients P
Serumphosphorus(pre-andpost-dialysis),mg/dl
Serumcalcium(pre-andpost-dialysis),mg/dl
Serum BUN (pre-dialysis),mg/d/
Serum creatinine (pre-dialysis), mg/dl
Serum alkaline phosphatase (pre-dialysis), lU/liter
5.1 2.6—* 2.6 1.3
9.2 0.6—f 11.0 0.5
72.5 14.5
15.8 4.8
140 51
6.1
9.4
2.2—f 3.1 0.9
0.8— 11.2 0.8
77.6 17.7
15.6 3.9
114 60
NS
NS
NS
NS
NS
a Values are the means SD.
Table 6. Results of radiologic skeletal surveys in June, July 1977
No. with No. with
subperiosteal pathologic
erosions fractures
Dead with dialysis dementia (N = 7) 0 5
Alive (N = 51)
Asymptomatic (N = 35) 2 6
Dialysis dementia symptoms(N=16) 0 11
a These results show the increased prevalence of pathologic
fractures and the relative absence of osteitis fibrosa. Of the 23
patients with dialysis dementia, 16 (70%) had pathologic frac-
tures.
possible especially if the disease is treated early
with purification of the dialysis fluid and reduction
in the oral load of aluminum. It is, of course, pos-
sible that other changes took place when the dial-
ysis fluid was purified, but at least we were able to
demonstrate a significant fall in serum aluminum
concentration, indicating that the previous alumi-
num excessive loading had ceased.
The benefit of electroencephalography in the di-
agnosis of this syndrome has been fully described
[1, 19, 21—23], and there is little doubt that in the
advanced stages of the disease, the EEG is in-
variably abnormal. (Fig. 1). What is not yet abso-
lutely clear is at what stage of the disease the EEG
becomes abnormal, whether early changes are in-
termittent and whether these EEG changes are spe-
cific for this disease. The current study showed that
5 out of the 16 affected patients had normal tracings
48 hours after the occurrence of the last set of
symptoms during hemodialysis, suggesting that
early EEG changes may be intermittent and that
more than one EEG tracing may be needed in order
to make an early diagnosis. Furthermore, the ob-
served changes do not appear to be specific to this
condition. The diffuse slowing of the normal brain
rhythm can be seen in several kinds of metabolic
encephalopathy, and even the more characteristic
paroxysmal, high voltage, slow delta waves maxi-
mal over the frontal areas can be seen in other neu-
rologic situations affecting azotaemic patients such
as uremic encephalopathy [27], severe hemodialysis
hypophosphatemia [28], and episodes of severe dis-
equilibrium [29]. Thus, all EEG findings should be
related to the patient's clinical condition before a
diagnosis of hemodialysis encephalopathy can be
made.
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Serum and tissue aluminum concentration:
water purification. The present study cannot pro-
vide a direct cause and effect relationship between
aluminum intoxication and dialysis encephalopathy
associated with osteomalacic pathologic fractures.
The clinical, radiologic, and histologic findings, to-
gether with the demonstrated high dialysate, serum
and tissue aluminum concentrations, do provide,
however, some evidence, which when viewed to-
gether with the epidemiologic studies in Denver [1,
19, 20], Eindhoven [4], Sheffield [5, 11], Newcastle
Upon Tyne [8, 30], Chicago [6, 22], Alma [7], and
France [31, 32], strongly indicate that aluminum
may be implicated in the pathogenesis of this com-
plex syndrome. Some doubt, however, must remain
that aluminum may not be the only facwr involved
in the pathogenesis of this syndrome, because
Platts, Goode, and Hislop [5] and Arieff et al [33]
were not able to confirm Aifrey' s original finding
that the gray matter brain aluminum concentration
in encephalopathic patients is significantly higher
than that of nonaffected hemodialysis patients.
On the other hand, this finding was reproduced by
Flendrig, Kruis, and Das [4], McDermott et al [30],
and Cartier et a! [31].
In the present study, tissue aluminum concentra-
tions in 5 encephalopathic patients were significant-
ly elevated, and serum aluminum concentrations
were high in the Columbia hemodialysis population
(Fig. 6). No correlation, however, could be demon-
strated between serum aluminum and the presence
or absence of encephalopathic symptoms or abnor-
mal EEG findings. This may in part reflect the varia-
bility and failure of serum aluminum to reflect
changes of tissue aluminum [8, 34], which may be
more important in determining the development of
the disease. Serum aluminum may indeed only re-
flect acute aluminum loading and as such may be
useful in identifying hemodialysis populations at risk
of developing aluminum intoxication. The most
convincing evidence for implicating aluminum in
the pathogenesis of this syndrome is the recent ex-
perimental study showing the production in rats of
an osteomalacic lesion identical to that found in
these encephalopathic patients [18]. Still, the neuro-
muscular toxicity of aluminum in experiments on
animals has been demonstrated at least since 1897
[35] and several times since then [36—38].
When hemodialysis encephalopathy was first de-
scribed, Alfrey et al considered oral aluminum con-
taining phosphate binders to be the main source of
the excess aluminum [20]. This, however, may not
be correct. In a survey carried out by the European
Dialysis and Transplant Association, the cumula-
tive oral aluminum dosage in 153 encephalopathic
patients was not higher than was that found in other
matched hemodialysis patients who did not develop
this complication [39]. Similarly, in one single unit,
Rosas, Port, and Rutt showed that the cumulative
dose of aluminum hydroxide in their encephalo-
pathic patients was not different from that con-
sumed by nonaffected patients [7]. It is also of inter-
est that despite thousands of nondialyzed azotaemic
patients receiving large quantities of these phos-
phate binders, the symptoms of dialysis encepha-
lopathy have only been described in 3 adult [21, 30,
40] and 5 pediatric such azotaemic patients [24].
These findings do not support the thesis that dial-
ysis encephalopathy is primarily the result of oral
aluminum-containing antacids. In contrast, there is
now good evidence indicating that aluminum enters
the body during hemodialysis when the dialysis fluid
aluminum concentration is inappropriately high [31,
34, 41]. It is, however, possible that the consump-
tion of excessive amounts of oral phosphate bind-
ers, such as extra-strength Basaljel, may aggravate
an already precarious situation.
Until 1977, no specific recommendations were
available in the United States regarding the alumi-
num content of dialysis fluid, and water standards
and techniques for preparing dialysis fluids were
'83.5 21.3 23.5 11.8 11.6 13.6'pg/liter13.5 9.4 6.5 4.5 7.5
Mean = 13.9
160 r-
140
120
a'
'100
E
.E 80
E
a'
E 60
=
a)U)
40
Normals June '77 April '78 Jan '78
Dec '77 June '77 May '78
20
0
Columbia, S.C. Mayo clinic
Fig. 6. Serial serum aluminum concentrations in hemodialysis
patients at Columbia, South Carolina, compared with controls
and also to patients dialyzing at the Mayo Clinic.
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quite variable. It has been argued that economic
factors prohibit the use of water softeners reverse
osmosis and deionizers in every hemodialysis unit.
Our experience, however, requires us to recom-
mend maximum water purification as the only way
to prevent unnecessary dangerous hemodialysis
complications. The overall installation costs of the
water purification plant were under $15,000, a small
amount compared to the expenses incurred during
the in-hospital and out-patient care of the patients
who developed these complications.
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